Table 4. Vaccine type availability and factors that influence choice of vaccine type by the GP in 2019/2020, by risk group, Austria.
| AUSTRIA | 9-17y | 18-64y | Chronic conditions or immunosuppression | ≥65y |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |
| Vaccine types available | (N = 51) | (N = 45) | (N = 53) | (N = 42) |
| 1 | 40 (78.4) | 38 (84.4) | 30 (56.6) | 23 (54.8) |
| >1 | 11 (21.6) | 7 (15.6) | 23 (43.4) | 19 (45.2) |
| The following factors influence choice of vaccine type by the GPa | (N = 11) | (N = 7) | (N = 23) | (N = 19) |
| Patient preference | 2 (18.2) | 2 (28.6) | 4 (17.4) | 5 (26.3) |
| Willingness to pay | 3 (27.3) | 1 (14.3) | 3 (13.0) | 5 (26.3) |
| Price | 1 (9.1) | 1 (14.3) | 2 (8.7) | 0 (0) |
| Directed by vaccine availability | 6 (54.5) | 3 (42.9) | 15 (65.2) | 12 (63.2) |
| Patient characteristics | 2 (18.2) | 1 (14.3) | 16 (69.6) | 14 (73.7) |
| The following patient characteristics influence choice of vaccine type by the GPb | (N = 2) | (N = 1) | (N = 14) | (N = 14) |
| Younger age | 1 (50.0) | 0 (0) | 4 (28.6) | 3 (21.4) |
| Older age | 2 (100) | 0 (0) | 14 (100.0) | 14 (100) |
| Presence of multiple comorbidities | 1 (50.0) | 0 (0) | 9 (64.3) | 6 (42.9) |
| Presence of specific comorbidities | 0 (0) | 1 (100) | 2 (14.3) | 1 (7.1) |
| Higher severity of comorbidities | 0 (0) | 0 (0) | 5 (35.7) | 5 (35.7) |
| Frailty | 0 (0) | 0 (0) | 4 (28.6) | 3 (21.4) |
| Profession | - | 1 (100) | - | - |
| Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
aTIV: adjuvanted trivalent influenza vaccine; n: number of GPs that chose a particular answer; N: number of GPs that answered the question; QIVe: egg-based quadrivalent influenza vaccine; QIVc: cell-based quadrivalent influenza vaccine.
a This question was only posed to GPs that answered “>1 type” to the previous question.
b This question was only posed to GPs that answered “patient characteristics” to the previous question.